Сайт предназначен для врачей


Список литературы

1.    World   Health   Organisation.   The   World Health Report 2000. Health systems: improving performance.  Geneva: World Health Organisation. 2000.

2.    Russian National Society for Atherothrombosis.  There is no atherothrombosis without atherosclerosis. Atherothrombosis bulletin. 2004;1:2.

3.    McNicol A., Israels S.J. Platelets and anti-platelet therapy. J. Pharmacol.  Sci.  2003;  93  (4):381-396.

4.    Patrono C. et al. Expert consensus document on the use of antiplatelet agents. Тhe task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur. Heart. J. 2004; 25 (2): 166-181.

5.    Smith S.C.Jr. et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) – executive summary. А report of the American College of Cardiology / American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions.   Circulation.  2001;   103   (24):3019-3041.

 6.   Storey R.F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets.2001; 12 (4): 197-209.

7.    Bertrand M.E. et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation   versus   Aspirin   and   Ticlopidine (FANTASTIC) study. Circulation. 1998; 98 (16): 1597-1603.

8.    Schomig A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl.J. Med. 1996; 334 (17): 1084-1089.

9.    Urban P. et al. Randomized evaluation of anti-coagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998; 98 (20): 2126-2132.

10.  Leon M.B. et al. A clinical trial comparing three  antithrombotic-drug  regimens  after coronary-artery stenting.  Stent Anticoagulation Restenosis Study Investigators. N. Engl.J. Med. 1998; 339 (23): 1665-1671.

11.  Bertrand M.E. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Тhe Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS).    Circulation.    2000;    102    (6):        18.624-629.

12.  Elias M., Reichman N., Flatau E. Bone marrow aplasia associated with ticlopidine therapy. Am.J. Hematol. 1993; 44 (4): 289-290.

13.  Montalescot G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON - TIMI 38).Double-blind, randomized controlled trial.Lancet. 2009; 373 (9665): 723-731.

14.  Sugidachi A. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br.J. Pharmacol. 2000; 129 (7): 1439-1446.

15.  Brandt J.T. et al. Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J. Am. Col. Cardiol. 2005; 45: 87A.Abstract 863-865.

16.  Asai E et al. A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers. J. Am.Col. Cardiol. 2005; 45: 87A. Abstract 865-868.

17.  Wiviott S.D. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO - TIMI 26) trial. Circulation. 2005; 111 (25): 3366-3373.

18.    Wiviott S.D. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation. 2007; 116 (25): 2923-2932.

19.    Wiviott S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl.J. Med. 2007; 357 (20): 2001-2015.

20.    Wiviott S.D. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in TRITON - TIMI 38. Circulation. 2008; 118 (16): 1626-1630.

21.    Wiviott S.D. et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON - TIMI 38 trial. А subanalysis of a randomised trial. Lancet. 2008; 371 (9621): 1353-1363.

22.    Murphy S.A. et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON - TIMI 38 trial. Eur. Heart. J. 2008; 29 (20): 2473-2479.


Импакт-фактор elibrary:
0,181 (АНГИОЛОГИЯ.ру) - портал о диагностике и лечении заболеваний сосудистой системы